Physician profile
Samyadev Datta
NPI 1497778005
$8,507.86
in general payments reported to CMS, 2019-2025
30 companies · $742 in 2025
The $742 reported for 2025 was more than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,408 · 2020: $378 · 2021: $653 · 2022: $3,026 · 2023: $445 · 2024: $856 · 2025: $742.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,043.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,043.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertos Medical, INC. | $3,036.25 | 2019-2024 | Mild Device Kit |
| Vertiflex, INC. | $1,068.26 | 2019 | |
| Abbott Laboratories | $709.47 | 2019-2025 | Proclaim, Eterna |
| Boston Scientific Corporation | $636.14 | 2019-2025 | Wavewriter Alpha Prime 16, Intracept Rf Probe |
| Collegium Pharmaceutical, INC. | $492.64 | 2019-2025 | Xtampza |
| Medtronic, INC. | $491.83 | 2021-2025 | Intellis Adaptivestim, Synchromedii, Inceptiv |
| Spr Therapeutics, INC | $324.76 | 2023-2025 | Sprint Pns System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $288.68 | 2019-2025 | Relistor |
| Relievant Medsystems, INC. | $256.64 | 2021-2023 | Intracept |
| Sentynl Therapeutics, INC. | $253.52 | 2019-2020 | |
| Pfizer INC. | $198.83 | 2019-2020 | |
| Biodelivery Sciences International, INC. | $126.57 | 2019-2021 | |
| Medtronic USA, INC. | $101.18 | 2019 | |
| Almatica Pharma LLC | $85.44 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $60.68 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $60.00 | 2019 | |
| Averitas Pharma INC. | $50.14 | 2024-2025 | Qutenza |
| Daiichi Sankyo INC. | $42.93 | 2019 | |
| Valinor Pharma, LLC | $35.90 | 2025 | Movantik |
| Protega Pharmaceutials INC | $33.98 | 2023 | Roxybond |
| Virtus Pharmaceuticals LLC | $25.36 | 2021 | |
| Tersera Therapeutics LLC | $19.96 | 2019 | |
| Nevro Corp. | $19.23 | 2023 | Senza |
| Merit Medical Systems INC | $16.36 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $15.94 | 2025 | |
| Scilex Pharmaceuticals INC. | $15.00 | 2019 | |
| Forte Bio-Pharma LLC | $14.84 | 2025 | Prolate, Nalocet, Tanlor |
| Redhill Biopharma INC. | $14.23 | 2021 | |
| Assertio Therapeutics, INC. | $13.10 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samyadev Datta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.